Nemours/Alfred I. duPont Hospital for Children
1701 Rockland Rd
Rockland One, Suite 150
Wilmington, DE 19803United States of Americahttp://www.nemours.org/pediatric-research/labservices/researchlabs/drug-discovery-lab.html
Last Updated: 10/01/2015
The Nemours High-Throughput Screening (HTS) & Drug Discovery Lab is one of only a few such facilities worldwide dedicated exclusively to technology development and drug discovery for rare childhood diseases underserved by current pharmaceutical development efforts. Projects are selected in pediatric disease areas where novel chemical probes will be useful to further biological understanding and to provide lead compounds for preclinical and clinical development.
Collaborations are sought with researchers having expertise in disease biology to develop assays for HTS and hit characterization and to screen compound libraries. Seed funding is used to generate preliminary data to support multi-PI grant applications. As an INBRE-affiliated Core Lab in the COBRE-funded Nemours Center for Pediatric Research, the HTS & Drug Discovery Lab collaborates with investigators from Delaware and
worldwide on target acquisition, assay development, and pilot HTS. Typically, this work will
be used to provide preliminary data for grant applications focused on HTS and chemical
probe discovery, for example PAR-12-058, Solicitation of Assays for High Throughput
Screening (HTS) to Discover Chemical Probes (R01).
Services encompass target selection, 384-well HTS compatible assay design & validation, pilot screening & target profiling (against pharmacologically active, well characterized compounds representing most target classes), HTS & follow-up with dose-response & selectivity testing of hits from 200,000 compound library, data analysis, and grant writing.
Nemours HTS & Drug Discovery lab expertise includes biochemical and cell-based assays
(enzymes, receptors, protein-protein interactions, protein-DNA interactions, cell viability, phenotypic screening), and detection technologies based on absorbance, fluorescence, luminescence, fluorescence polarization, time-resolved fluorescence, and AlphaScreen.
The lab is headed by Dr. Andrew Napper, who established the HTS & Drug Discovery laboratory at the Nemours Center for Childhood Cancer
Research (NCCCR) in 2009. Dr. Napper has over 25 years of drug discovery experience and was previously Director of High-Throughput Screening for the Penn Center for Molecular Discovery at
the University of Pennsylvania (one of the original 10 centers established as part of the NIH Roadmap initiative to discover drugs for neglected diseases). Current group reporting to Dr. Napper consists of an HTS Scientist/Lab Manager with more than 20 years of experience in pharmaceutical and academic drug discovery, a Postdoctoral Fellow, a Research Associate, and a recent faculty appointee. In the summer undergraduate scholars join the group.
Facilities include new 2,200 sq. ft. purpose-built lab and office space designed specifically for assay development, high-throughput screening(HTS), and hit-to-lead drug discovery (opened 2011); liquid handling workstations, reagent dispensers, and plate readers equipped with stackers and barcode readers; a fully equipped tissue culture and sterile screening lab adjoining the main HTS lab; and a freezer bay for cryostorage of cell lines, compounds and reagents.
Services are offerred outside of Nemours/Alfred I. duPont Hospital for Children
Consulting is offerred outside of Nemours/Alfred I. duPont Hospital for Children